Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Jacob R. Haling"'
Autor:
Anke Bill, Sheryll Espinola, Daniel Guthy, Jacob R. Haling, Mylene Lanter, Min Lu, Anthony Marelli, Angelica Mendiola, Loren Miraglia, Brandon L. Taylor, Leonardo Vargas, Anthony P. Orth, Frederick J. King
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-6 (2021)
Bill et al describe two high-throughput methods to detect protein-protein interactions in cells in real-time using the split-NanoLuciferase-complementation system. They demonstrate the methods can detect exogenously (RT-bind) or endogenously (EndoBin
Externí odkaz:
https://doaj.org/article/e6bdb53a936c41a9bbda86784fa7f7a5
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Autor:
Darrin D. Stuart, William R. Sellers, Savithri Ramurthy, Emma Lees, Michael P. Dillon, Nicholas Keen, Mallika Singh, Payman Amiri, Mohammad Hekmat-Nejad, Richard Zang, Valery Polyakov, Robert Aversa, Jacob R. Haling, John Tellew, Alice Rico, Gisele Nishiguchi, Lesley A. Mathews Griner, Joshua M. Korn, Fang Shen, Yingyun Wang, Stacy Rivera, Vesselina G. Cooke, Giordano Caponigro, Yun Feng, Yuji M. Mishina, Wenlin Shao
Antiproliferative effect of RAF709 compared to dabrafenib, trametinib, RAF265 and sorafenib across a tumor cell panel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df399afb7bc4b33e7cbabf7feb9002be
https://doi.org/10.1158/0008-5472.22417724
https://doi.org/10.1158/0008-5472.22417724
Autor:
Darrin D. Stuart, William R. Sellers, Savithri Ramurthy, Emma Lees, Michael P. Dillon, Nicholas Keen, Mallika Singh, Payman Amiri, Mohammad Hekmat-Nejad, Richard Zang, Valery Polyakov, Robert Aversa, Jacob R. Haling, John Tellew, Alice Rico, Gisele Nishiguchi, Lesley A. Mathews Griner, Joshua M. Korn, Fang Shen, Yingyun Wang, Stacy Rivera, Vesselina G. Cooke, Giordano Caponigro, Yun Feng, Yuji M. Mishina, Wenlin Shao
Legends for supplemental figures and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ecd2476f2638a45906022d87ad08b63
https://doi.org/10.1158/0008-5472.22417733.v1
https://doi.org/10.1158/0008-5472.22417733.v1
Autor:
Darrin D. Stuart, William R. Sellers, Savithri Ramurthy, Emma Lees, Michael P. Dillon, Nicholas Keen, Mallika Singh, Payman Amiri, Mohammad Hekmat-Nejad, Richard Zang, Valery Polyakov, Robert Aversa, Jacob R. Haling, John Tellew, Alice Rico, Gisele Nishiguchi, Lesley A. Mathews Griner, Joshua M. Korn, Fang Shen, Yingyun Wang, Stacy Rivera, Vesselina G. Cooke, Giordano Caponigro, Yun Feng, Yuji M. Mishina, Wenlin Shao
Table S1: Kinase hits from KinomeScan panel. Table S4: Antiproliferative activity of RAF709 in a Ba/F3 cell kinase panel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c1dd2a0d5312e56631333a731f162e6
https://doi.org/10.1158/0008-5472.22417721.v1
https://doi.org/10.1158/0008-5472.22417721.v1
Autor:
Darrin D. Stuart, William R. Sellers, Savithri Ramurthy, Emma Lees, Michael P. Dillon, Nicholas Keen, Mallika Singh, Payman Amiri, Mohammad Hekmat-Nejad, Richard Zang, Valery Polyakov, Robert Aversa, Jacob R. Haling, John Tellew, Alice Rico, Gisele Nishiguchi, Lesley A. Mathews Griner, Joshua M. Korn, Fang Shen, Yingyun Wang, Stacy Rivera, Vesselina G. Cooke, Giordano Caponigro, Yun Feng, Yuji M. Mishina, Wenlin Shao
Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the activated BRAF oncogene. Here, we report antitumor properties of RAF709, a novel ATP-competitive kinase inhibitor with high potency and selectivity against RAF kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19b65b9e42831ecdc7ded906b41fb312
https://doi.org/10.1158/0008-5472.c.6509918
https://doi.org/10.1158/0008-5472.c.6509918
Autor:
Darrin D. Stuart, William R. Sellers, Savithri Ramurthy, Emma Lees, Michael P. Dillon, Nicholas Keen, Mallika Singh, Payman Amiri, Mohammad Hekmat-Nejad, Richard Zang, Valery Polyakov, Robert Aversa, Jacob R. Haling, John Tellew, Alice Rico, Gisele Nishiguchi, Lesley A. Mathews Griner, Joshua M. Korn, Fang Shen, Yingyun Wang, Stacy Rivera, Vesselina G. Cooke, Giordano Caponigro, Yun Feng, Yuji M. Mishina, Wenlin Shao
Figure S1: pMEK and pERK suppression in KRAS mutant and BRAFV600E cells by dabrafenib or RAF709. Figure S2: pMEK and pERK suppression in NRAS mutant and BRAFV600E cells by dabrafenib or RAF709. Figure S3: Cell cycle and apoptotic effects of RAF709 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0fe7cfebf3508787efa87cdc0ecc11
https://doi.org/10.1158/0008-5472.22417736
https://doi.org/10.1158/0008-5472.22417736
Autor:
Mari Manuia, Wenshuo Lu, Laura J. Kingsley, Zhiwei Ma, Vicki Zhou, Darbi Witmer, Glen Spraggon, Mu-Yun Gao, Pierre-Yves Michellys, Min Lu, Yong Jia, Matthew McNeill, Sarah Greenblatt, Bender Steven Lee, Andreas Kreusch, Gerald Lelais, Xiaohui He, Victor Nikulin, Mei-Ting Vaillancourt, Christian C. Lee, Jacob R. Haling, John Nelson, Ajay A. Vashisht
Publikováno v:
Journal of Medicinal Chemistry. 64:4857-4869
LONP1 is an AAA+ protease that maintains mitochondrial homeostasis by removing damaged or misfolded proteins. Elevated activity and expression of LONP1 promotes cancer cell proliferation and resistance to apoptosis-inducing reagents. Despite the impo
Autor:
Shilpi Khare, Niranjan Sudhakar, Jade Laguer, David M. Briere, Larry Yan, Allan Hebbert, Andrew Calinisan, Lars D. Engstrom, Fadia Qiryaqos, Peter Olson, James G. Christensen, Jacob R. Haling
Publikováno v:
Cancer Research. 83:3499-3499
Osimertinib is a third generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recommended as a first line therapy in patients with advanced non-small lung cancer (NSCLC) characterized by EGFR activating mutations (
Autor:
Jill, Hallin, Vickie, Bowcut, Andrew, Calinisan, David M, Briere, Lauren, Hargis, Lars D, Engstrom, Jade, Laguer, James, Medwid, Darin, Vanderpool, Ella, Lifset, David, Trinh, Natalie, Hoffman, Xiaolun, Wang, J, David Lawson, Robin J, Gunn, Christopher R, Smith, Nicole C, Thomas, Matthew, Martinson, Alex, Bergstrom, Francis, Sullivan, Karyn, Bouhana, Shannon, Winski, Leo, He, Julio, Fernandez-Banet, Adam, Pavlicek, Jacob R, Haling, Lisa, Rahbaek, Matthew A, Marx, Peter, Olson, James G, Christensen
Publikováno v:
Nature medicine. 28(10)
Recent progress in targeting KRAS